Search

An abstract of the case study "Idiopathic granulomatous mastitis as a complication of interferon-alpha theraphy," by H. Shaaban and colleagues is presented.

This article discusses two case reports of women with idiopathic granulomatous mastitis (IGM) who did not respond to various treatments, including prednisolone, methotrexate, colchicine, and nonsteroidal anti-inflammatory drugs (NSAIDs). One of the women also developed breast ulcers while being treated with imiquimod. However, both patients showed improvement when imiquimod was added to their treatment regimens. The article provides details about the patients' symptoms, treatments, and outcomes, highlighting the potential efficacy of imiquimod for IGM. [Extracted from the article]

A case series involving 19 female patients with granulomatous mastitis was described. Among them, 11 patients experienced various adverse effects during treatment with prednisone, methotrexate, sirolimus, or mycophenolate-mofetil, including emotional lability, palpitations, insomnia, bloating, metallic taste, liver function tests derangement, alopecia, moon face, steroid-induced myopathy, steroid-induced hyperglycemia, weight gain, reflux, nausea, fatigue, miscarriage, diarrhea, headaches, skin infection, or bacterial conjunctivitis. Nine of these patients received these medications during pregnancy. Some patients also exhibited lack of efficacy with prednisone or methotrexate. Four patients discontinued their therapy. Overall, while some patients experienced adverse effects and lack of efficacy, others showed improvement with their respective treatments. [Extracted from the article]

The article presents a case study of a 41-year-old woman who experienced hyperprolactinaemia and idiopathic granulomatous mastitis while she was treated with risperidone for her schizophrenic condition.

A 38-year-old woman developed Brucellosis while being treated with prednisolone for idiopathic granulomatous mastitis. She initially presented with a painful mass and was treated with antibiotics, but had no response. After diagnostic tests confirmed the diagnosis of IGM, she started receiving prednisolone and experienced symptom resolution. However, two months later, she developed joint pain and headache and was diagnosed with Brucellosis secondary to prednisolone. She was treated with doxycycline and rifampicin, along with continued prednisolone, and her symptoms improved. At one-year follow-up, her IGM was in remission. [Extracted from the article]

The article describes the case of a 39-year-old woman who received risperidone but she developed hyperprolactinaemia and iopathic granulomatous mastitis during treatment.

The primigravid woman, presented with a several-month history of bilateral breast lumps, associated with tenderness, decreased sensation, skin thickening and pruritus at 19 weeks of gestation. Differential diagnosis included breast carcinoma, morphea profunda, granulomatous mastitis, lupus mastitis and diffuse DDA. In addition to a diagnosis of DDA, she was additionally diagnosed with gestational gigantomastia (GG), and rheumatology had concern of lupus mastitis. [Extracted from the article]

However, three months later, despite the treatment erythematous swelling of the right breast developed indicating lack of efficacy to prednisolone and methotrexate. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 33-year-old woman developed granulomatous mastitis (GM) during treatment with sulpiride for depression. Additionally, she developed weight gain and abdominal striae during treatment with prednisolone and exhibited lack of efficacy during treatment with prednisolone and methotrexate for GM [ I routes and duration of treatments to reactions onsets not stated; not all outcomes stated i ] I . i The nulliparous woman who had history of depression had been receiving treatment with sulpiride 200mg twice daily. [Extracted from the article]

Histopathological examination of the excised mass confirmed the diagnosis of granulomatous mastitis. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 24-year-old woman exhibited lack of efficacy while receiving antibacterial therapy with piperacillin during pregnancy. Hence, antibacterial therapy was started with IV piperacillin [ I dosage not stated i ]; however, after three days of treatment, persistent worsening of symptoms was noted. [Extracted from the article]

Additionally, she experienced weight gain during treatment with prednisone for idiopathic granulomatous mastitis [ I routes, durations of treatments to reactions onsets and outcomes not stated; not all dosages stated i ]. To avoid adverse effects of steroids and to maintain disease control, prednisone was tapered and methotrexate was added. After methotrexate was stopped, multiple exacerbations of her underlying disease were noted in 2016 and 2017, despite aggressive prednisone treatment. [Extracted from the article]

As a result, oral methotrexate was replaced by SC methotrexate. Subsequently, her idiopathic granulomatous mastitis relapsed, as SC methotrexate was held because of a lapse in contraception and elevated liver function test [ I time to reaction onset and outcome not stated i ]. [Extracted from the article]

The article describes the case of a 15-year-old girl who received quinine for Falciparum malaria but she developed bronchiolitis obliterans and organising pneumonia following treatment.

An abstract of the case study "Purple tongue: a rare side effect resulting from peginterferon alpha 2a and rebavirin treatment in a patient with chronic hepatitis C," by K. Elghonemy and colleagues is presented.

An abstract of a case study "Superficial venous thromboplebitis associated with pegylated interferon alpha-2a treatment in a patient with chronic hepatitis B," by M. Kalafateli and colleagues is presented.

An abstract of a case study "Permanent anosmia in a patient treated with pegylated interferon alpha," by N. Rahman and colleagues is presented.

An abstract of the article "Risperidone induced granulomatous mastitis secondary to hyperprolactinemia in a non-pregnant woman-a rare case report in a bipolar disorder," by S. N. Holla and colleagues is presented.

An abstract of the case study "Phenytoin-induced autoimmune hepatitis," by H. Y. Jhun and colleagues is presented.

An abstract of the case study "A Case of Tardive Dyskinesia due to Olanzapine Treatment," by S. Zincir and colleagues is presented.

The article presents a case study of a 50-year old woman who developed paradoxical reaction, granulomatous mastitis and aseptic osteitis during treatment with adalimumab for palmoplantar pustular psoriasis.

The article presents case report of two patients who developed hyperprolactinaemia and granulomatous mastitis, following administration of sulpiride, and fluphenazine respectively.

An abstract of the article "Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: A case report," by M. A. Sahraian and colleagues is presented.

An abstract of the article "Idiopathic granulomatous mastitis: a mimicking disease in a pregnant woman: a case report," by J. A. Garcia-Rodriguez is presented.

The article describes the case of an HIV-positive 40-year-old woman who developed acute liver failure (ALF) while receiving highly active antiretroviral therapy (HAART), inclusive of emtricitabine, nevirapine and tenofovir.

The article describes the case of a 12-year-old girl who developed a severe Jarisch-Herxheimer reaction following treatment with intravenous (IV) doxycycline for tick-borne relapsing fever.

The article describes the case of a 68-year-old woman who developed palmar-plantar erythrodysaesthesia following administration of doxorubicin liposomal as second-line chemotherapy.

The article describes the case of a 14-year-old girl presented with suspected autoimmune encephalitis secondary to anti-NMDAR antibodies who experienced hypersensitivity after receiving an intravenous (IV) rituximab.